Date:8/8/2011

fficulties or delays in manufacturing material for clinical studies; ADVENTRX's reliance on third parties to assist in the conduct of important aspects of its product candidates' development programs, and that such third parties may fail to perform as expected; the potential for ADVENTRX to raise additional capital to acquire new technologies, product candidates or products and/or to fund development and/or commercialization activities for current and/or future product candidates; the risk that ADVENTRX will pursue acquisition and/or development activities at levels on timelines, or will incur unexpected expenses, that shorten the period through which its operating funds will sustain it; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at www.sec.gov.

You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date hereof, except as may be required by law.

[Tables to Follow]ADVENTRX Pharmaceuticals, Inc.(A Development Stage Enterprise)Condensed Consolidated Statements of Operations(Unaudited)(In 000's except per share data)Three months ended June 30,Six months ended June 30,2011201020112010Total net revenue

$
8212;$
8212;$
8212;$
8212;Operating expenses:Research and development

1,3436341,9541,873Selling, general and administrative

1,8241,3033,3982,478Transaction-related expenses

1,230—2,029—Depreciation and amortization

1062012Total operating expenses

4,4071,9437,4014,363Loss from operations

(4,407)(1,943)(7,401)(4,363)Interest and other income

'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. ADVENTRX Pharmaceuticals to Present at the 31st Annual Canaccord Genuity Growth Conference on August 11
2. Vista Partners Initiates Coverage on ADVENTRX Pharmaceuticals, Inc.; Target Price $7.50
3. ADVENTRX Reports First Quarter 2011 Financial Results
4. ADVENTRX Completes Acquisition of SynthRx
5. ADVENTRX Pharmaceuticals Provides Update on ANX-514
6. ADVENTRX Signs Definitive Agreement to Acquire SynthRx Inc.
7. ADVENTRX to Provide Update Regarding Pipeline Expansion Efforts
8. ADVENTRX Pharmaceuticals to Present at the 13th Annual BIOCEO & Investor Conference on February 15
9. ADVENTRX Pharmaceuticals Receives PDUFA Date for Exelbine™ NDA
10. ADVENTRX Pharmaceuticals Announces Closing of $22.5 Million Financing
11. ADVENTRX Pharmaceuticals Announces Capital Raise of $22.5 Million